What is a primary concern when prescribing antipsychotics in children?

Prescribing antipsychotics in children raises several concerns, with metabolic syndrome being a primary issue. Metabolic syndrome encompasses a range of conditions, including obesity, hyperglycemia, dyslipidemia, and hypertension, which can significantly impact a child's physical health and well-being over time. The risk of developing these metabolic side effects is heightened in pediatric populations due to their ongoing physical and neurological development.

Antipsychotic medications, particularly atypical antipsychotics, have been associated with notable weight gain, changes in glucose metabolism, and lipid abnormalities, making vigilance essential in monitoring these children. The prevalence of metabolic syndrome in children treated with antipsychotics warrants careful assessment and regular follow-up to mitigate these risks and ensure that any signs of metabolic changes are identified and addressed promptly.

While cognitive dysfunction, increased aggression, and sleep disturbances are valid considerations when treating children with antipsychotics, they are not as universally prominent or as directly associated with long-term health outcomes as metabolic syndrome. This is why metabolic syndrome stands out as a significant concern in this context.